Expert Anticipates Expansion of Targeted Therapies Aimed at Resistance in Breast Cancer

Jane De Lartigue, PhD
Published: Wednesday, Sep 11, 2019
Adam M. Brufsky, MD, PhD, medical director of the MageeWomen's Cancer Program at the University of Pittsburgh Medical Center Hillman Cancer Center

Adam M. Brufsky, MD, PhD

Many new strategies to address resistance in patients with estrogen receptor (ER)–positive breast cancer are in the works, thanks to a greater understanding of the cell-signaling networks activated during the course of disease and treatment, according to Adam M. Brufsky, MD, PhD. He expects many targeted agents, particularly in the adjuvant setting, to become available as clinical investigations mature.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Publication Bottom Border
Border Publication